Swiss drugmaker Novartis AG (NVS) doesn't plan any changes to its agreement with Nestle SA (NESN.VX) on eye-care company Alcon Inc. (ACL), management said during a conference call Thursday, detailing the company's first-quarter results.

Novartis is in the process of buying Alcon from Nestle for a total of $39 billion. The deal is expected to be concluded by 2010 or 2011.

In a first step, Basel-based Novartis paid Nestle $10.4 billion for a 25% stake in Alcon in July 2008.

Nestle now has the right to sell its remaining 52% stake in Alcon between January 2010 and July 2011 to Novartis at a 20% premium of the average share price during the week before the sale, not exceeding $181 a share, or $28 billion.

Nestle has the right to require Novartis to buy this stake, though there is a walkaway clause in the case of unexpected events such as a major product recall.

Company Web Site: www.novartis.com; www.nestle.com

-By Julia Mengewein, Dow Jones Newswires; +41 43 443 80 45; julia.mengewein@dowjones.com